<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-60480</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">UPLIFT. The UPLIFT study: future perspectives</dc:title>
<dc:description xml:lang="en">The natural history of chronic obstructive pulmonarydisease (COPD) has classically been considered in terms ofthe rapid decrease in forced expiratory volume in 1 second(FEV1) and no other measure apart from smoking cessationhas been demonstrated to modify the speed of this decrease.The evidence available from studies performed withtiotropium, of up to 1 year&#146;s duration, have shown that thisanticholinergic drug can modify the course of COPD byacting on lung function, air entrapment, exacerbations,dyspnea and exercise tolerance, thus improving healthstatus. This evidence has served as the basis for the design ofthe UPLIFT study (Understanding Potential Long-termImpacts on Function with Tiotropium), the main aim ofwhich is to determine the effect of tiotropium on diseaseprogression. This multicenter and multinational study haslasted for 4 years and almost 6,000 patients with COPDhave participated. Data from this study are currently beinganalyzed and the results will shortly be made known. If theresults are positive, it will be the first time that apharmacological intervention has been able to modify therate of FEV1 decline, which would imply that the underlyingdisease is truly being modified. Positive data from theUPLIFT study would indicate that, together with smokingcessation, early treatment with tiotropium should beinitiated at any stage of COPD, since both measures wouldhave been proven to be able to modify the natural course ofthe disease. The probability of demonstrating maintenanceof bronchodilation, as well as maintenance of the decrease inthe number and severity of exacerbations found in studiesconducted over a 1-year period, would represent a realchange in what has been known to date about the naturalcourse of COPD(AU)</dc:description>
<dc:creator>Lucas Ramos, Pilar de</dc:creator>
<dc:creator>Rodríguez González-Moro, José Miguel</dc:creator>
<dc:creator>Lucero, Soledad</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Actualmente se encuentra en la fase de análisis de datos y está próxima la comunicación de los resultados. Si del estudio UPLIFT se derivaran resultados positivos, sería la primera vez que una medida farmacológica es capaz de modificar la tasa de caída del FEV1, lo que implicaría que la enfermedad subyacente está siendo verdaderamente modificada. Los datos positivos del UPLIFT apoyarían que, junto al abandono del hábito tabáquico, se debería iniciar tratamiento con tiotropio en cualquier estadio de la EPOC, ya que ambas medidas se habrían mostrado capaces de modificar la evolución natural de la enfermedad. La probabilidad de demostrar el mantenimiento de la broncodilatación, así como el mantenimiento en el tiempo de la disminución del número y de la gravedad de las exacerbaciones encontrada en los estudios a un año, abre la puerta a un auténtico cambio en los datos conocidos hasta ahora sobre la evolución natural de la EPOC(AU)</dc:description>
<dc:source>Arch Bronconeumol;44(supl.2): 39-48, jul. 2008. ilus, tab, graf</dc:source>
<dc:identifier>ibc-60480</dc:identifier>
<dc:title xml:lang="es">Estudio UPLIFT: perspectivas futuras</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d36008^s22032</dc:subject>
<dc:subject>^d2021^s22073</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d28041</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33882</dc:subject>
<dc:subject>^d4479^s22080</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:type>article</dc:type>
<dc:date>200807</dc:date>
</metadata>
</record>
</ibecs-document>
